<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110819">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01739465</url>
  </required_header>
  <id_info>
    <org_study_id>RFA2012</org_study_id>
    <nct_id>NCT01739465</nct_id>
  </id_info>
  <brief_title>Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable Cholangiocarcinoma</brief_title>
  <official_title>A Randomized Controlled Trial Comparing Endoscopic Biliary Radiofrequency Ablation With Photodynamic Therapy for Inoperable Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Medical University</source>
  <oversight_info>
    <authority>China: Science and Technology Commission of Guangzhou</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare endoscopic radiofrequency ablation with photodynamic
      therapy for inoperable cholangiocarcinoma
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>stent patency</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival rate</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>Self expanding metallic stent （SEMS ）placement only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) would be performed to confirm the position and length of the biliary malignant. A self expanding metallic stent (SEMS) would be placed to bypass the site of narrowing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endoscopic radiofrequency ablation plus SEMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) would be performed to confirm the position and length of the biliary malignant. The radiofrequency ablation (RFA) catheter (EMcision, London, United Kingdom) would be placed under fluoroscopic guidance across the biliary stricture. Radiofrequency energy will be delivered to the malignant site. After that,A self expanding metallic stent (SEMS) would be placed to bypass the site of narrowing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Photodynamic therapy plus SEMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Photofrin is injected 3 days prior to laser activation of the agent.Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC)  will be carried out to determine the length and positon of the biliary malignant. Delivery Fiber used along with the laser system to activate the photosensitizing agent and induce tumor tissue necrosis. A self expanding metallic stent (SEMS) will be placed the site of biliary narrowing</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Self expanding metallic stent (SEMS)</intervention_name>
    <description>Self expanding metallic stent</description>
    <arm_group_label>Self expanding metallic stent （SEMS ）placement only</arm_group_label>
    <arm_group_label>Endoscopic radiofrequency ablation plus SEMS</arm_group_label>
    <arm_group_label>Photodynamic therapy plus SEMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic radiofrequency ablation (ERFA)</intervention_name>
    <description>Endoscopic radiofrequency ablation</description>
    <arm_group_label>Endoscopic radiofrequency ablation plus SEMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Photodynamic therapy (PDT)</intervention_name>
    <description>Photodynamic therapy</description>
    <arm_group_label>Photodynamic therapy plus SEMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old

          -  Pathologically or radiologically confirmed biliary malignant

          -  Inoperability by staging

        Exclusion Criteria:

          -  Cholangiocarcinoma with widespread metastasis

          -  Coagulopathy (INR &gt; 2.0 or prothrombin time &gt; 100 sec or platelet count &lt; 50,000)

          -  Prior SEMS placement

          -  Pregnancy

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≥ 3 )

          -  Life expectancy &lt; 3months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Huihong Liang, MD</last_name>
    <phone>+86-20-34153043</phone>
    <email>beanth@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second Hospital of Guangzhou Medical College</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510260</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Huihong Liang, MD</last_name>
      <phone>+86-188-2648-8232</phone>
      <email>beanth@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The second hospital of Guangzhou Medical college</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510260</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huihong Liang, Doctorial</last_name>
      <phone>+86-188-2648-8232</phone>
      <email>beanth@163.com</email>
    </contact>
    <investigator>
      <last_name>Huihong Liang, Doctoral</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 25, 2013</lastchanged_date>
  <firstreceived_date>November 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou Medical University</investigator_affiliation>
    <investigator_full_name>Huihong Liang</investigator_full_name>
    <investigator_title>Associated Professor</investigator_title>
  </responsible_party>
  <keyword>Cholangiocarcinoma</keyword>
  <keyword>Pathologic</keyword>
  <keyword>Digestive System</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Bile Duct Diseases</keyword>
  <keyword>Biliary Tract Diseases</keyword>
  <keyword>Pathological Conditions</keyword>
  <keyword>Constriction</keyword>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Carcinoma</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
